GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma

BACKGROUND: Aggressive primary brain tumors such as glioblastoma are uniquely challenging to treat. The intracranial location poses barriers to therapy, and the potential for severe toxicity. Effective treatments for primary brain tumors are limited, and 5-year survival rates remain poor. Immune che...

Descripción completa

Detalles Bibliográficos
Autores principales: Gargett, Tessa, Ebert, Lisa M, Truong, Nga T H, Kollis, Paris M, Sedivakova, Kristyna, Yu, Wenbo, Yeo, Erica C F, Wittwer, Nicole L, Gliddon, Briony L, Tea, Melinda N, Ormsby, Rebecca, Poonnoose, Santosh, Nowicki, Jake, Vittorio, Orazio, Ziegler, David S, Pitson, Stuart M, Brown, Michael P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516307/
https://www.ncbi.nlm.nih.gov/pubmed/36167468
http://dx.doi.org/10.1136/jitc-2022-005187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516307/
https://www.ncbi.nlm.nih.gov/pubmed/36167468
http://dx.doi.org/10.1136/jitc-2022-005187

Ejemplares similares